文拉法辛,临床注释-2,变异和临床注释数据

文拉法辛

临床注释ID

982037423

药物名称(英)

venlafaxine

变异单倍型

CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

117.5

PMID计数

计数的证据

表现型

抑郁症；强迫症

表现型(英)

Depressive Disorder;Obsessive-Compulsive Disorder

最新日期

2021/5/3 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/982037423

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
602	*10	The CYP2D610 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the 10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.
601	*6	The CYP2D66 allele has been assigned as a no function allele by CPIC. Patients carrying the 6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.
600	*5	The CYP2D65 allele has been assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.
599	*4	The CYP2D64 allele has been assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.
598	*3	The CYP2D63 allele has been assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the 3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the 3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.
597	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of venlafaxine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of venlafaxine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.

临床证据

id	证据的ID	总结
2966	1183681035	CYP2D6 4/5 is associated with decreased metabolism of venlafaxine in a person with depression.
2965	1450815182	CYP2D6 4/5 is associated with decreased metabolism of venlafaxine.
2964	1183617359	CYP2D6 3/4 + 4/4 + 4/5 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 1/1.
2963	982029525	CYP2D6 1/3 + 1/4 + 1/5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 1/1.
2962	1447950037	CYP2D6 10/10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 1/1 + 1/2.
2961	982029646	CYP2D6 5/10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 1/1.
2960	982029627	CYP2D6 10/10 is associated with increased venlafaxine Cmax and AUC when treated with venlafaxine in healthy individuals as compared to CYP2D6 1/1.
2959	982029604	CYP2D6 1/10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 1/1.
2958	982029591	CYP2D6 10/10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 1/1.
2957	982029511	CYP2D6 4/4 is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 1/1.
2956	982029490	CYP2D6 4/4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 1/1.
2955	982029371	CYP2D6 4/4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 1/1.
2954	982029364	CYP2D6 1/4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 1/1.
2953	982015108	Genotypes CT + TT are associated with increased venlafaxine concentration per unit dose when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.
2952	750192626	Allele del is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele A.
2951	769143878	Allele T is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele C.
2950	1451252940	CYP2D6 poor metabolizer phenotype is associated with decreased clearance of venlafaxine as compared to CYP2D6 normal metabolizer phenotype.
2949	PA166104968	Annotation of DPWG Guideline for venlafaxine and CYP2D6

临床病史

id	类型	评论
846	Update	Added DPWG guideline to evidence. Moved uncertain function alleles to new CA. Rewrote phenotype descriptions to fit LOE 1A template.
845	Update	CA score added as part of scoring system release. LOE assigned following curator review.
844	Update	modified CA to only over PK studies
843	Update	Added PMID 23332809 to evidence

最新招商产品更多>>